Free Webex Call
The Global Nanomedicine Market is expected to grow at an impressive CAGR of 8.28% in the forecast period, 2023-2027, to reach USD242655.19 million by 2027. The market is driven by the factors such as the growing healthcare expenditure and increased demand for personalized medicines. The massive prevalence of chronic and lifestyle disorders such as cancer and cardiovascular diseases across the globe is accelerating the application of nanomedicine in various healthcare applications. Also, the high-end investments in research and development activities by public and private players to find novel solutions for drug delivery and increase the effectiveness of drugs are expected to create lucrative growth opportunities for the Global Nanomedicine Market in the forecast period. Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Nanomedicines are considered very effective in treating chronic diseases such as cancer, dementia, and diabetes as they fuel the metabolism of medications in the body. They deliver the drugs at the target site in the right proportion. The market's availability of nanomedical products such as DNA probes, nanosensors, and nanoparticle-based imaging agents is increasing the demand. However, the high cost associated with the nanomedicine manufacturing process and research and development activities may hinder the Global Nanomedicine Market in the forecast period.
The Global Nanomedicine Market is divided into nano molecule type, nanoparticles type, application, disease indication, regional distribution, and competitive landscape. Based on application, the nanomedicine market is divided into drug delivery, vaccines, diagnostic imaging, regenerative medicine, and others. Drug delivery applications dominated the market in 2021 and captured 30.23% of the overall market share. This segment is expected to maintain its dominance over the next five years. The rise in awareness about the benefits of nanomedicine in drug delivery applications and the increased prevalence of diseases drives the demand for nanomedicines for drug delivery applications.
The major market players operating in the Global Nanomedicine Market are Pfizer Inc., Janssen Pharmaceuticals, Sanofi S.A., Amgen Inc., Moderna, Inc., Novo Nordisk A/S, Genentech, Inc., Celgene Corporation, Vifor Pharma Group, Teva Pharmaceutical Industries Ltd., among others.
Years considered for this report:
- Historical Years: 2017-2020
- Base Year: 2021
- Estimated Year: 2022
- Forecast Period: 2023-2027
Objective of the Study:
- To analyze the historical growth and the market size of the Global Nanomedicine Market from 2017 to 2021.
- To estimate and forecast the market size of the Global Nanomedicine Market from 2023 to 2027 and growth rate until 2027.
- To classify and forecast the Global Nanomedicine Market is divided into nanomolecule type, nanoparticles type, application, disease indication, regional distribution, and competitive landscape.
- To identify drivers and challenges for the Global Nanomedicine Market.
- To examine competitive developments such as expansions, new product launches, mergers, and acquisitions, etc., in the Global Nanomedicine Market.
- To conduct pricing analysis for the Global Nanomedicine Market.
- To identify and analyze the profile of leading players operating in the Global Nanomedicine Market.
The publisher calculated the Global Nanomedicine Market size by using a bottom-up approach, where data for various regions was recorded and forecasted for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Nanomedicine manufacturers/ suppliers/ distributors
- Government bodies such as regulating authorities and policy makers
- Organizations, forums, and alliances related to nanomedicine
- Market research and consulting firms
Report Scope:
In this report, the Global Nanomedicine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Nanomedicine Market, By Nanomolecule Type:
- Nanoparticles
- Nanoshells
- Nanodevices
- Nanotubes
Nanomedicine Market, By Nanoparticles Type:
- Polymer-based
- Lipid-based
- Nanocrystals
- Inorganic
- Others
Nanomedicine Market, By Application:
- Drug Delivery
- Vaccines
- Diagnostic Imaging
- Regenerative Medicine
- Others
Nanomedicine Market, By Disease Indication:
- Oncological Diseases
- Infectious Diseases
- Orthopedic Disorders
- Cardiovascular Diseases
- Others
Nanomedicine Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Denmark
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Malaysia
- Vietnam
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- Turkey
- Israel
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Nanomedicine Market.
Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs.
Table of Contents
1. Product Overview2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Nanomedicine Market
5. Voice of Customer
5.1. Factors Increasing the demand for Nanomedicine
5.2. Preference, By Nanomolecule Type
5.3. Demand for Nanomedicine, By Indication
5.4. Brand Awareness
6. Global Nanomedicine Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
6.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
6.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
6.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
6.2.4. By Company (2021)
6.2.5. By Region
6.3. Market Map
7. North America Nanomedicine Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
7.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
7.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
7.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Nanomedicine Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Nanomolecule Type
7.3.1.2.1.1. By Nanoparticle Type
7.3.1.2.2. By Application
7.3.1.2.3. By Disease Indication
7.3.2. Canada Nanomedicine Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Nanomolecule Type
7.3.2.2.1.1. By Nanoparticle Type
7.3.2.2.2. By Application
7.3.2.2.3. By Disease Indication
7.3.3. Mexico Nanomedicine Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Nanomolecule Type
7.3.3.2.1.1. By Nanoparticle Type
7.3.3.2.2. By Application
7.3.3.2.3. By Disease Indication
8. Europe Nanomedicine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
8.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
8.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
8.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. Germany Nanomedicine Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Nanomolecule Type
8.3.1.2.1.1. By Nanoparticle Type
8.3.1.2.2. By Application
8.3.1.2.3. By Disease Indication
8.3.2. France Nanomedicine Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Nanomolecule Type
8.3.2.2.1.1. By Nanoparticle Type
8.3.2.2.2. By Application
8.3.2.2.3. By Disease Indication
8.3.3. United Kingdom Nanomedicine Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Nanomolecule Type
8.3.3.2.1.1. By Nanoparticle Type
8.3.3.2.2. By Application
8.3.3.2.3. By Disease Indication
8.3.4. Italy Nanomedicine Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Nanomolecule Type
8.3.4.2.1.1. By Nanoparticle Type
8.3.4.2.2. By Application
8.3.4.2.3. By Disease Indication
8.3.5. Spain Nanomedicine Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Nanomolecule Type
8.3.5.2.1.1. By Nanoparticle Type
8.3.5.2.2. By Application
8.3.5.2.3. By Disease Indication
8.3.6. Denmark Nanomedicine Market Outlook
8.3.6.1. Market Size & Forecast
8.3.6.1.1. By Value
8.3.6.2. Market Share & Forecast
8.3.6.2.1. By Nanomolecule Type
8.3.6.2.1.1. By Nanoparticle Type
8.3.6.2.2. By Application
8.3.6.2.3. By Disease Indication
9. Asia Pacific Nanomedicine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
9.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
9.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
9.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
9.2.4. By Country
9.3. Asia Pacific: Country Analysis
9.3.1. China Nanomedicine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Nanomolecule Type
9.3.1.2.1.1. By Nanoparticle Type
9.3.1.2.2. By Application
9.3.1.2.3. By Disease Indication
9.3.2. Japan Nanomedicine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Nanomolecule Type
9.3.2.2.1.1. By Nanoparticle Type
9.3.2.2.2. By Application
9.3.2.2.3. By Disease Indication
9.3.3. India Nanomedicine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Nanomolecule Type
9.3.3.2.1.1. By Nanoparticle Type
9.3.3.2.2. By Application
9.3.3.2.3. By Disease Indication
9.3.4. Australia Nanomedicine Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Nanomolecule Type
9.3.4.2.1.1. By Nanoparticle Type
9.3.4.2.2. By Application
9.3.4.2.3. By Disease Indication
9.3.5. South Korea Nanomedicine Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Nanomolecule Type
9.3.5.2.1.1. By Nanoparticle Type
9.3.5.2.2. By Application
9.3.5.2.3. By Disease Indication
9.3.6. Malaysia Nanomedicine Market Outlook
9.3.6.1. Market Size & Forecast
9.3.6.1.1. By Value
9.3.6.2. Market Share & Forecast
9.3.6.2.1. By Nanomolecule Type
9.3.6.2.1.1. By Nanoparticle Type
9.3.6.2.2. By Application
9.3.6.2.3. By Disease Indication
9.3.7. Vietnam Nanomedicine Market Outlook
9.3.7.1. Market Size & Forecast
9.3.7.1.1. By Value
9.3.7.2. Market Share & Forecast
9.3.7.2.1. By Nanomolecule Type
9.3.7.2.1.1. By Nanoparticle Type
9.3.7.2.2. By Application
9.3.7.2.3. By Disease Indication
10. South America Nanomedicine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
10.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
10.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
10.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Nanomedicine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Nanomolecule Type
10.3.1.2.1.1. By Nanoparticle Type
10.3.1.2.2. By Application
10.3.1.2.3. By Disease Indication
10.3.2. Argentina Nanomedicine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Nanomolecule Type
10.3.2.2.1.1. By Nanoparticle Type
10.3.2.2.2. By Application
10.3.2.2.3. By Disease Indication
10.3.3. Colombia Nanomedicine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Nanomolecule Type
10.3.3.2.1.1. By Nanoparticle Type
10.3.3.2.2. By Application
10.3.3.2.3. By Disease Indication
11. Middle East and Africa Nanomedicine Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes)
11.2.1.1. By Nanoparticle Type (Polymer - based, Lipid - based, Nanocrystals, Inorganic, Others)
11.2.2. By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others)
11.2.3. By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others)
11.2.4. By Country
11.3. Middle East and Africa: Country Analysis
11.3.1. Turkey Nanomedicine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Nanomolecule Type
11.3.1.2.1.1. By Nanoparticle Type
11.3.1.2.2. By Application
11.3.1.2.3. By Disease Indication
11.3.2. Israel Nanomedicine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Nanomolecule Type
11.3.2.2.1.1. By Nanoparticle Type
11.3.2.2.2. By Application
11.3.2.2.3. By Disease Indication
11.3.3. South Africa Nanomedicine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Nanomolecule Type
11.3.3.2.1.1. By Nanoparticle Type
11.3.3.2.2. By Application
11.3.3.2.3. By Disease Indication
11.3.4. Saudi Arabia Nanomedicine Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Nanomolecule Type
11.3.4.2.1.1. By Nanoparticle Type
11.3.4.2.2. By Application
11.3.4.2.3. By Disease Indication
11.3.5. UAE Nanomedicine Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Nanomolecule Type
11.3.5.2.1.1. By Nanoparticle Type
11.3.5.2.2. By Application
11.3.5.2.3. By Disease Indication
11.3.6. Kuwait Nanomedicine Market Outlook
11.3.6.1. Market Size & Forecast
11.3.6.1.1. By Value
11.3.6.2. Market Share & Forecast
11.3.6.2.1. By Nanomolecule Type
11.3.6.2.1.1. By Nanoparticle Type
11.3.6.2.2. By Application
11.3.6.2.3. By Disease Indication
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends and Developments
14. Competitive Landscape
14.1. Pfizer Inc.
14.2. Janssen Pharmaceuticals
14.3. Sanofi S.A.
14.4. Amgen Inc.
14.5. Moderna, Inc.
14.6. Novo Nordisk A/S
14.7. Genentech, Inc
14.8. Celgene Corporation
14.9. Vifor Pharma Ltd.
14.10. Teva Pharmaceutical Industries Ltd.
15. Strategic RecommendationsList of FiguresFigure 1: Global Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 2: Global Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 3: Global Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 4: Global Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 5: Global Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 6: Global Nanomedicine Market Share, By Region, By Value, 2017-2027F
Figure 7: Global Nanomedicine Market Share, By Company, By Value, 2021
Figure 8: Global Nanomedicine Market Map, By Nanomolecule Type, Market Size (USD Million) & Growth Rate (%), 2021
Figure 9: North America Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 10: North America Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 11: North America Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 12: North America Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 13: North America Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 14: North America Nanomedicine Market Share, By Country, By Value, 2017-2027F
Figure 15: United States Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 16: United States Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 17: United States Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 18: United States Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 19: United States Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 20: Canada Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 21: Canada Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 22: Canada Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 23: Canada Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 24: Canada Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 25: Mexico Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 26: Mexico Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 27: Mexico Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 28: Mexico Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 29: Mexico Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 30: Europe Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 31: Europe Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 32: Europe Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 33: Europe Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 34: Europe Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 35: Europe Nanomedicine Market Share, By Country, By Value, 2017-2027F
Figure 36: Germany Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 37: Germany Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 38: Germany Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 39: Germany Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 40: Germany Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 41: France Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 42: France Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 43: France Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 44: France Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 45: France Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 46: United Kingdom Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 47: United Kingdom Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 48: United Kingdom Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 49: United Kingdom Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 50: United Kingdom Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 51: Italy Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 52: Italy Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 53: Italy Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 54: Italy Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 55: Italy Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 56: Spain Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 57: Spain Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 58: Spain Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 59: Spain Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 60: Spain Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 61: Denmark Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 62: Denmark Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 63: Denmark Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 64: Denmark Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 65: Denmark Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 66: Middle East & Africa Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 67: Middle East & Africa Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 68: Middle East & Africa Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 69: Middle East & Africa Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 70: Middle East & Africa Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 71: Middle East & Africa Nanomedicine Market Share, By Country, By Value, 2017-2027F
Figure 72: China Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 73: China Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 74: China Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 75: China Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 76: China Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 77: Japan Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 78: Japan Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 79: Japan Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 80: Japan Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 81: Japan Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 82: India Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 83: India Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 84: India Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 85: India Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 86: India Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 87: Australia Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 88: Australia Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 89: Australia Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 90: Australia Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 91: Australia Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 92: South Korea Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 93: South Korea Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 94: South Korea Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 95: South Korea Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 96: South Korea Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 97: Malaysia Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 98: Malaysia Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 99: Malaysia Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 100: Malaysia Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 101: Malaysia Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 102: Vietnam Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 103: Vietnam Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 104: Vietnam Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 105: Vietnam Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 106: Vietnam Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 107: South America Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 108: South America Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 109: South America Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 110: South America Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 111: South America Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 112: South America Nanomedicine Market Share, By Country, By Value, 2017-2027F
Figure 113: Brazil Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 114: Brazil Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 115: Brazil Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 116: Brazil Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 117: Brazil Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 118: Argentina Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 119: Argentina Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 120: Argentina Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 121: Argentina Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 122: Argentina Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 123: Colombia Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 124: Colombia Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 125: Colombia Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 126: Colombia Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 127: Colombia Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 128: Middle East & Africa Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 129: Middle East & Africa Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 130: Middle East & Africa Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 131: Middle East & Africa Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 132: Middle East & Africa Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 133: Middle East & Africa Nanomedicine Market Share, By Country, By Value, 2017-2027F
Figure 134: Turkey Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 135: Turkey Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 136: Turkey Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 137: Turkey Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 138: Turkey Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 139: Israel Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 140: Israel Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 141: Israel Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 142: Israel Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 143: Israel Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 144: South Africa Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 145: South Africa Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 146: South Africa Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 147: South Africa Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 148: South Africa Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 149: Saudi Arabia Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 150: Saudi Arabia Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 151: Saudi Arabia Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 152: Saudi Arabia Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 153: Saudi Arabia Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 154: UAE Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 155: UAE Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 156: UAE Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 157: UAE Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 158: UAE Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Figure 159: Kuwait Nanomedicine Market Size, By Value (USD Million), 2017-2027F
Figure 160: Kuwait Nanomedicine Market Share, By Nanomolecule Type, By Value, 2017-2027F
Figure 161: Kuwait Nanomedicine Market Share, By Nanoparticle Type, By Value, 2017-2027F
Figure 162: Kuwait Nanomedicine Market Share, By Application, By Value, 2017-2027F
Figure 163: Kuwait Nanomedicine Market Share, By Disease Indication, By Value, 2017-2027F
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Janssen Pharmaceuticals
- Sanofi S.A.
- Amgen Inc.
- Moderna, Inc.
- Novo Nordisk A/S
- Genentech, Inc
- Celgene Corporation
- Vifor Pharma Ltd.
- Teva Pharmaceutical Industries Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 111 |
| Published | June 2022 |
| Forecast Period | 2017 - 2027 |
| Estimated Market Value ( USD | $ 121758.97 Million |
| Forecasted Market Value ( USD | $ 242655.19 Million |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
